Method for treating neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-10583125-B2
Application number	US-201916298422-A
Country	US
Kind code	B2
Filing date	Mar 11, 2019
Priority date	Oct 14, 2014
Publication date	Mar 10, 2020
Grant date	Mar 10, 2020

Abstract

The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

First claim

What is claimed is:

1. A method of suppressing microglia-mediated inflammation in a subject diagnosed with a neurodegenerative disease, comprising the step of administering to a subject suffering from a neurodegenerative disease an effective amount of a solvate or pharmaceutically acceptable salt of 2-(4-tert-butylphenyl)-1H-benzimidazole.

2. The method of claim 1 , wherein the neurodegenerative disease is selected from the group consisting of: amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, and a demyelinating disease.

3. The method according to claim 1 , wherein said compound is administered by systemic administration.

4. The method according to claim 1 , wherein said compound is administered by oral administration.

5. The method of claim 2 , wherein the neurodegenerative disease is ALS.

6. The method of claim 2 , wherein the neurodegenerative disease is Alzheimer's disease.

7. The method of claim 2 , wherein the neurodegenerative disease is Parkinson's disease.

8. The method of claim 2 , wherein the neurodegenerative disease is Huntington's disease.

9. The method of claim 2 , wherein the neurodegenerative disease is frontotemporal degeneration.

10. The method of claim 2 , wherein the neurodegenerative disease is dementia with Lewy bodies.

11. The method of claim 2 , wherein the neurodegenerative disease is a motor neuron disease.

12. The method of claim 2 , wherein the neurodegenerative disease is a demyelinating disease.

Assignees

• Univ Leland Stanford Junior
• The Board Of Trustees Of The Leland Stanford Junio

Inventors

• Nguyen Khoa Dinh
• Engleman Edgar G

Classifications

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C07D235/18

  with aryl radicals directly attached in position 2 · CPC title

• A61K31/41

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• C12Q1/68

  involving nucleic acids · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title